[HTML][HTML] Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis
C Rodriguez-Mogeda, ZYGJ van Lierop… - Journal of …, 2023 - Springer
Background Recent studies suggest that extended interval dosing of ocrelizumab, an anti-B
cell therapy, does not affect its clinical effectiveness in most patients with multiple sclerosis …
cell therapy, does not affect its clinical effectiveness in most patients with multiple sclerosis …
[HTML][HTML] CD19 cell count at baseline predicts B cell repopulation at 6 and 12 months in multiple sclerosis patients treated with ocrelizumab
G Abbadessa, G Miele, P Cavalla, P Valentino… - International Journal of …, 2021 - mdpi.com
Background: The kinetics of B cell repopulation in MS patients treated with Ocrelizumab is
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
highly variable, suggesting that a fixed dosage and time scheduling might be not optimal …
Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis
Background Long-term B cell depletion with ocrelizumab in multiple sclerosis (MS) is
associated with severe side effects such as hypogammaglobulinemia and infections. Our …
associated with severe side effects such as hypogammaglobulinemia and infections. Our …
Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis
A Mathias, V Pantazou, S Perriot… - Neurology …, 2023 - AAN Enterprises
Background and Objective Depleting CD20+ B cells is the primary mechanism by which
ocrelizumab (OCRE) is efficient in persons with multiple sclerosis (pwMS). However, the …
ocrelizumab (OCRE) is efficient in persons with multiple sclerosis (pwMS). However, the …
Ocrelizumab for the treatment of multiple sclerosis: safety, efficacy, and pharmacology
CR Mancinelli, ND Rossi, R Capra - Therapeutics and Clinical …, 2021 - Taylor & Francis
The success of selective B-cells depleting therapies, as the anti-CD20 antibodies, in patients
with multiple sclerosis (MS) has confirmed that B-cells are critical in the immune …
with multiple sclerosis (MS) has confirmed that B-cells are critical in the immune …
BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab
E Signoriello, S Bonavita, A Di Pietro… - Multiple Sclerosis and …, 2020 - Elsevier
Objectives Ocrelizumab (OCR) is a humanized monoclonal antibody targeting CD20 antigen
exposed on B cells surface. Kinetic of B-cells repopulation after depletion therapy shows …
exposed on B cells surface. Kinetic of B-cells repopulation after depletion therapy shows …
[HTML][HTML] Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
[HTML][HTML] Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
S Gingele, TL Jacobus, FF Konen, MW Hümmert… - Cells, 2018 - mdpi.com
Ocrelizumab, a humanized monoclonal anti-CD20 antibody, has shown pronounced effects
in reduction of disease activity in multiple sclerosis (MS) patients and has recently been …
in reduction of disease activity in multiple sclerosis (MS) patients and has recently been …
Effect of ocrelizumab on B-and T-cell receptor repertoire diversity in patients with relapsing multiple sclerosis from the randomized phase III OPERA trial
Background and Objectives The B cell–depleting anti-CD20 antibody ocrelizumab (OCR)
effectively reduces MS disease activity and slows disability progression. Given the role of B …
effectively reduces MS disease activity and slows disability progression. Given the role of B …
[HTML][HTML] Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study
N Capasso, R Palladino, V Cerbone, AL Spiezia… - Journal of …, 2023 - Springer
Objective We aim to evaluate 3-year effects of ocrelizumab (humanized anti-CD20
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …
monoclonal antibody for the treatment of multiple sclerosis (MS)) on lymphocytes …